SGLT2 is responsible for reabsorbing up to 90% (animal data) of the glucose filtered at the glomerulus. The remaining 10% (animal data) is reabsorbed by SGLT1 that is expressed on the luminal (brush border) surface of cells of the S3 segment of the proximal tubule
Pathophysiology of Diabetic Nephropathy and role of SGLT2
Glomerular hyperfiltration over a long period of time is associated with podocyte stress and loss.
Over a period of time podocyte loss leads to glomerulosclerosis and atrophy
"We should be paying more attention to the proximal tubule" @ChristosArgyrop
A picture says a 1000 words-- the magic word is decreasing hyperfiltration
Why? maybe.. Increase glucagon levels– increase mg absorption in the distal tubule; Decrease in insulin levels – leading to movement of Mg to extracellular volume; Hemoconcentration related?; Reduced Mg excretion-effect on ion channel 6; insulin resistant effect on mg wasting
What else can they do? Improve Anemia in CKD
More EPO production as less effect of #hif
For the #onconephrology world- basic science study canagliflozin significantly attenuates cisplatin-induced nephropathy in C57BL/6 mice and suppresses cisplatin induced renal proximal tubular cell apoptosis in vitro. journals.physiology.org/doi/full/10.11…
Large analysis showing less kidney stones @weddellite@DMalieckal --- hmmm #flozinate for stone prevention..maybe the increase urine flow, decreased uric acid levels increased fluid intake by patients given being on SGLT2i link.springer.com/article/10.100… END PART 1
What about Scrt... SGLT2i therapy can cause an acute drop in eGFR. In the absence of hemodynamic instability or an alternate cause of AKI, the initial decline in GFR by 4-8 ml/min/1.73m2 after SGLT2i initiation is likely due to reduction in intra-glomerular pressure.
A typical patient included in CREDENCE would lose 4.6 ml/min/year of eGFR if treated with RAASi only, reaching ESKD in 10 years. However, if canagliflozin is added to his treatment, he would only lose 1.85 ml/min/year of eGFR, delaying ESKD by 15 kidney360.asnjournals.org/content/early/…
2. Most data regarding outcomes of kidney transplantation in patients with myeloma come from single center case series. With the advent of novel treatment choices, it remains unclear if outcomes of kidney transplant recipients with myeloma have improved in last decade
3.Literature reviews for multiple myeloma or smoldering MM with kidney transplantation were performed. Case series with at least one kidney transplant recipient with a history of multiple myeloma were included.